Navigation Links
GeoVax Labs Reports 2012 First Quarter Financial Results
Date:5/15/2012

icate superior protection when compared to similar viral challenge studies for competitive vaccine designs currently in human clinical trials. We are therefore very excited about the potential for our vaccine."

Dr. McNally continued, "On the financial side, we continue to benefit from NIH/HVTN support of our human clinical trials and we are seeking additional government support to fund our internal research and development activities to expand the use of our technology against strains (clades) of the HIV virus affecting other areas of the globe. From December 2011 to March 2012, we raised a total of $2.7 million in equity capital to bolster our cash reserves."

Comment on Gilead Science's Truvada® Prevention SubmissionDr. McNally also commented on the recent news related to an advisory panel's recommendation that the FDA approve Gilead Science's submission of their anti-viral medication, Truvada, for prevention of HIV. "While any positive step towards the control of this deadly disease is greatly welcomed, we must continue the search for safe, cost-effective measures to prevent HIV transmission. The high cost of oral medications, patient compliance, and risk of medical side effects clearly suggest the best solution still lies with a preventive vaccine. GeoVax's preventive vaccine is considered a leading candidate for the version of the virus prevalent in North and South America, and Europe."

Financial ReviewGeoVax reported a net loss for the three months ended March 31, 2012 of $730,513, or $0.04 per share, based on 16.7 million weighted average shares outstanding. For the three months ended March 31, 2011, the Company reported a loss of $606,282, or $0.04 per share, based on 15.7 million weighted average shares outstanding.

The Company reported revenues of $854,063 for the three months ended March 31, 2012, related to its Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) grant from the National Institutes
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. GeoVax Labs CEO Update Letter to Shareholders
2. GeoVax Labs First Patient Inoculated in Phase 1/2 Clinical Trial for HIV/AIDS Therapeutic Vaccine
3. GeoVax Phase 2a Clinical Trial Completes Enrollment
4. GeoVax $3.6 Million Award Increased to $4.4 Million by U.S. Government
5. GeoVax Labs, Inc. Announces Second Quarter Financial Results
6. GeoVax Labs HIV/AIDS Vaccine Development Leadership to be Highlighted During 2011 World Vaccine Congress
7. GeoVax Announces Publication of Phase 1 Clinical Trial in The Journal of Infectious Diseases
8. GeoVax Launches a Second Clinical Site to Test the Therapeutic Benefit of its HIV Vaccine
9. David A. Dodd Appointed Chairman of the Board of GeoVax Labs
10. GeoVax Announces Expansion of Phase 2a Human HIV/AIDS Vaccine Trial
11. GeoVax Awarded Federal Grant Under the Qualifying Therapeutic Discovery Project Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... , June 02, 2015 Research and ... the "Specialty Enzymes - Global Strategic Business Report" ... is also analyzed by the following End-Use Applications: Pharmaceutical ... separate comprehensive analytics for the US, Canada ... Europe , Asia-Pacific , ...
(Date:6/2/2015)... 2015 Today the Council of State ... food companies, retailers, and human and animal health ... Stewardship. CSTE is committed to supporting changes that ... strains, preserve the efficacy of our existing antibiotics, ... CSTE continues to serve as a key ...
(Date:6/2/2015)... June 2, 2015 ANI Pharmaceuticals, Inc. ("ANI") ... received approval from the U.S. Food and Drug Administration ... Oxycodone Hydrochloride Oral Solution 5mg/5mL. Trailing twelve-month sales for ... three current competitors. ANI expects to begin shipping to ... , President and CEO of ANI Pharmaceuticals, stated, "This ...
Breaking Medicine Technology:Specialty Enzymes - Global Strategic Business Report 2015: Indispensable to the Pharmaceutical Industry 2ANI Pharmaceuticals Announces FDA Approval of Oxycodone Hydrochloride Oral Solution 5mg/5mL 2ANI Pharmaceuticals Announces FDA Approval of Oxycodone Hydrochloride Oral Solution 5mg/5mL 3
... DALLAS, March 10 ACCESS PHARMACEUTICALS, INC.,(OTC Bulletin Board: ... conference call for March 13, 2008 at 10:00 a.m. ... its clinical trial programs as,well as its business opportunities., ... dialing (877),407-8293; callers outside the U.S. may participate by ...
... Reported at AAOS Annual Meeting Support Longterm ... ... GENZ ), today announced findings from a large, multicenter,observational study that ... had pain and,functional impairment from defects in the articular cartilage of ...
Cached Medicine Technology:Access Pharmaceuticals to Conduct Conference Call to Update Financial Community 2Genzyme Announces Presentation of New Positive Data on Carticel(R) 2Genzyme Announces Presentation of New Positive Data on Carticel(R) 3Genzyme Announces Presentation of New Positive Data on Carticel(R) 4Genzyme Announces Presentation of New Positive Data on Carticel(R) 5Genzyme Announces Presentation of New Positive Data on Carticel(R) 6
(Date:6/2/2015)... NC (PRWEB) June 02, 2015 ... training and compliance solutions for the healthcare market, ... The Arc to offer 10 complimentary courses relating ... provide public safety professionals with additional resources to ... Safety professionals are often the first responders to ...
(Date:6/2/2015)... Baltimore, MD (PRWEB) June 02, 2015 ... a Baltimore-based creative marketing, web design and development agency, ... initiative. , National Autism Resources’ new website ... with people of all ages diagnosed with autism. The ... community and offer an array of resources, from easy ...
(Date:6/2/2015)... With the approaching summer shaping up as ... United States, people will spend an increasing amount of ... of air conditioning, a recent CBS News article* warned ... allergic reactions. Fresh water advocate Sharon Kleyne, host of ... will discuss the potential side effects of air conditioning ...
(Date:6/2/2015)... PhishLine, LLC today announced it will ... Suite 125 in Waukesha, Wisconsin 53186. The ... of operations for PhishLine’s current corporate staff and ... Mark Chapman, Founder and President, commented “PhishLine is ... customers adopt our market leading service to address ...
(Date:6/2/2015)... Residents of Monarch Landing in Naperville are ... fitness class, do yoga, play volleyball, or participate in ... the Alzheimer’s Association’s Walk to End Alzheimer’s on September ... in a challenge to exercise for 60 days, sponsored ... , While the walk will raise awareness of Alzheimer’s ...
Breaking Medicine News(10 mins):Health News:Relias Learning Partners with Behavioral Health and Developmental Disabilities Leaders to Offer Complimentary Resources to Public Safety Professionals 2Health News:Relias Learning Partners with Behavioral Health and Developmental Disabilities Leaders to Offer Complimentary Resources to Public Safety Professionals 3Health News:National Autism Resources Launches New Website, Delivering More Products and Services 2Health News:National Autism Resources Launches New Website, Delivering More Products and Services 3Health News:Air conditioning may contribute to dry eye, dehydration and allergies warns fresh water advocate Sharon Kleyne 2Health News:Air conditioning may contribute to dry eye, dehydration and allergies warns fresh water advocate Sharon Kleyne 3Health News:PhishLine, LLC Announces New Corporate Headquarters 2Health News:Monarch Landing Takes 60-Day Exercise Challenge to Combat Alzheimer’s 2Health News:Monarch Landing Takes 60-Day Exercise Challenge to Combat Alzheimer’s 3
... Associates will host a community health fair in the Shoh-Sohail ... will include free health screenings for the local community, will ... VHA Building on the Mandalay Canal, 220 Las Colinas Blvd, ... will be hosted in an effort to inform, educate and ...
... the availability of Trade Alerts on stocks making news today. ... free by visiting: http://www.BeaconEquity.com/m Today,s Trade Alerts include: ... (NYSE: ABT ), Eli Lilly & Co. (NYSE: ... ), Novartis AG (NYSE: NVS ) and GlaxoSmithKline ...
... Feb. 18 SpectraScience, Inc. (OTC Bulletin Board: ... it will place its LUMA(R) Cervical Imaging System ... located in Edina, Minnesota.Dr. James B. Presthus, co-founder ... of the LUMA System represents our continued dedication ...
... affairs departments in deploying comprehensive investigator-initiated research grant management program ... ... 18, 2009 -- Clinipace, a growing clinical research solutions company, ... firms to deploy its TEMPO™ for Grant Management ...
... is warranted, experts say , , WEDNESDAY, Feb. 18 (HealthDay News) ... human fetal stem cell therapy has been reported in Moscow, ... to the growths. , The tumors appeared along ... after he began receiving the neural fetal stem cell treatment ...
... Feb. 18 Inverness Medical Innovations, Inc. (NYSE: ... charge of their health at home through the merger of ... for the quarter ended December 31, 2008.In the fourth quarter ... compared to net revenue of $288.0 million in the fourth ...
Cached Medicine News:Health News:Las Colinas FREE Community Health Fair Benefiting the Shoh-Sohail Family of Irving 2Health News:Beacon Equity Issues Technical Trade Alerts on Drug Manufacturers: JNJ, ABT, LLY, PFE, NVS, GSK 2Health News:LUMA Cervical Imaging System Installed in Edina at Minnesota Gynecology 2Health News:LUMA Cervical Imaging System Installed in Edina at Minnesota Gynecology 3Health News:Two Pharmaceutical Firms Select Clinipace to Deploy New Grant Management Solution 2Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 2Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 3Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 4Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 5Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 6Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 7Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 8Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 9Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 10Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 11Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 12Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 13Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 14Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 15Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 16Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 17Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 18
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: